Elevation Oncology (NASDAQ:ELEV) stock drops as the company shifts focus to solid tumor therapy EO-1022, halts EO-3021 development after weak data. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback